


3rd Edition

Karsten Conrad, Werner Schöblier, Falk Hiepe, Marvin J. Fritzler

Autoantibodies in Systemic Autoimmune Diseases

A Diagnostic Reference



AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY
Volume 2, third Edition – 2015

PABST

AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY

Edited by: K. Conrad (Dresden, Germany)
U. Sack (Leipzig, Germany)
Vol. 2, third Edition – 2015

Authors

PD Dr. Karsten Conrad
Institute for Immunology
Medical Faculty of the Technical University Dresden
Fetscherstraße 74
01307 Dresden, GERMANY
Phone: +49 (0) 351-458-6540
Fax: +49 (0) 351-458-6308
E-mail: K_Conrad@mail.zih.tu-dresden.de

Dr. Werner Schöblier
Rathenastr. 12
16341 Panketal, GERMANY
Fax: +49 (0) 30-983-119-94
E-mail: Dr.Schoessler@arcor.de

Univ.-Prof. Dr. Falk Hiepe
Charité University Hospital
Department of Rheumatology & Clinical Immunology
Charitéplatz 1
10117 Berlin, GERMANY
Phone: +49 (0) 30-450-513012
Fax: +49 (0) 30-450-51392
E-mail: Falk.Hiepe@charite.de

Marvin J. Fritzler, MD, PhD
Professor of Medicine
Arthritis Society Chair
Faculty of Medicine
University of Calgary
Calgary, Alberta, CANADA
Phone: +01 403-220-3533
Fax: +01 403-283-5666
E-mail: Fritzler@ucalgary.ca

Karsten Conrad, Werner Schöblier, Falk Hiepe, Marvin J. Fritzler

Autoantibodies in Systemic Autoimmune Diseases

A Diagnostic Reference

3rd Edition

AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY
Volume 2, third Edition – 2015



PABST SCIENCE PUBLISHERS
Lengerich, Berlin, Bremen, Miami,
Riga, Viernheim, Wien, Zagreb

Bibliographic information published by Deutsche Nationalbibliothek
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulation and therefore free for general use.

The authors and the publisher of this volume have taken care that the information and recommendations contained herein are accurate and compatible with the standards generally accepted at the time of publication. Nevertheless, it is difficult to ensure that all the information given is entirely accurate for all circumstances. The publisher disclaims any liability, loss, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this volume.

© 2015 Pabst Science Publishers, 49525 Lengerich

<http://www.pabst-publishers.de>

Printing: Neue Druckhaus Dresden GmbH, Germany
Typesetting+cover+production: partzwo KG, Chemnitz, Germany
Copyproof: Dr. Silke Zwjatkow, Dresden, Germany

ISBN 978-3-89967-883-3
eBook 978-3-89967-999-1

Contents

Preface, 3rd edition	XVII
Preface, 1st edition	XVIII
Notes for the Use of this Book	1
Autoantibodies – Definitions and Characteristics	3
Autoantibodies in the Diagnosis of Autoimmune Diseases	4

Part 1

Autoantibodies in Systemic Autoimmune Diseases

ACPA	12
Alanyl-tRNA (tRNA ^{Ala}) Synthetase Antibodies	12
Alpha-Actinin Antibodies	12
Alpha-Enolase Antibodies	12
Alpha-Fodrin Antibodies	14
Aminoacyl-tRNA Synthetase Antibodies	16
Annexin V Antibodies	18
Antineutrophil Cytoplasmic Antibodies (ANCA)	20
Antinuclear Antibodies (ANA)	23
ASE-1 Antibodies	25
Asparaginyl-tRNA (tRNA ^{Asp}) Synthetase (ARS) Antibodies	26
Assemblysome Antibodies	26
AT1R Antibodies	26
AUF1 Antibodies	27
Azurocidin Antibodies	27
Beta-Fodrin Antibodies	29
Beta2 Glycoprotein I (β2-GPI) Antibodies	29
BPI Antibodies	33
BRAF Antibodies	35
C1D Antibodies	35
C1q Antibodies	35

CADM-140 Antibodies	37
Calpastatin Antibodies	37
Calreticulin Antibodies	38
cANCA (C-ANCA)	39
Cardiolipin Antibodies	41
CarP Antibodies	44
Cathepsin G Antibodies	45
CCP Antibodies	45
CD16 Antibodies	47
CD74 Antibodies	47
CENP-A Antibodies	48
CENP-B Antibodies	48
CENP-C Antibodies	49
CENP-E Antibodies	49
CENP-F Antibodies	50
CENP-H Antibodies	52
CENP-O Antibodies	52
Centriole Antibodies	53
Centromere Antibodies	53
Centrophilin Antibodies	56
Centrosome Antibodies	56
CEP-1 Antibodies	58
Chromatin Antibodies	59
Chromo Antibodies	59
Citrullinated Protein/Peptide Antibodies	60
CLIP Antibodies	62
Coilin Antibodies	62
Collagen Antibodies	63
CRP Antibodies	65
Cryoglobulins	66
Cytoplasmic Linker Protein170 (CLIP-170) Antibodies	67
DEK Antibodies	67
DFS70 Antibodies	68
Double-Stranded DNA (dsDNA) Antibodies	70
EEA-1 Antibodies	74
EF1A Antibodies	75
EJ Antibodies	76
Elastase Antibodies	76
ENA Antibodies	76
Endothelial Cell Antibodies	77
EPCR Antibodies	79
ET _A R Antibodies	79

Exosome Antibodies	79
Fer Antibodies	80
Ferritin Antibodies	80
Fibrillarin Antibodies	80
Fibrillin 1 Antibodies	82
Fibroblast Antibodies.	83
Filaggrin Antibodies.	83
Galectin Antibodies	84
Galectin-1 Antibodies	84
Galectin-2 Antibodies	85
Glutamyl-tRNA (tRNA ^{Glu}) Synthetase Antibodies	85
Glycyl-tRNA (tRNA ^{Gly}) Synthetase Antibodies	85
GM1 Antibodies	85
Golgi Apparatus Antibodies	86
Gu Antibodies.	88
GWB Antibodies.	88
Heat Shock Protein (Hsp) Antibodies	90
Histidyl-tRNA (tRNA ^{His}) Synthetase (HRS) Antibodies	91
Histone Antibodies	91
HMG Antibodies.	94
HMGB1 Antibodies	95
HMGR Antibodies	95
hnRNPAntibodies	96
hnRNP-A2 Antibodies	99
hnRNP-D Antibodies	99
HsEg5 Antibodies.	99
5-HT4 Receptor Antibodies.	100
Human Neutrophil Elastase (HNE) Antibodies	101
IFI 16 Antibodies	101
IgA Autoantibodies	103
Isoleucyl-tRNA (tRNA ^{Ile}) Synthetase Antibodies	104
Ja Antibodies	104
Jo-1 Antibodies	104
Keratin Antibodies (AKA).	106
Ki Antibodies	107
Kinectin Antibodies	108
KJ Antibodies	108
KS Antibodies	109
Ku Antibodies	110
L5/5S Antibodies	113
L7 Antibodies	113
L12 Antibodies	114

Lactoferrin Antibodies	114
Lamin Antibodies	114
LAMP-2 Antibodies	115
La/SS-B Antibodies	116
LE Cell Factor	118
LEDGF Antibodies	120
Leucyl-tRNA (tRNA ^{Leu}) Synthetase Antibodies	120
Lipoprotein Lipase (LPL) Antibodies	120
Lupus Anticoagulant (LA)	121
Lysobisphosphatidic Acid (LBPA) Antibodies	124
Lysosome Antibodies	124
Lysozyme Antibodies	125
Lysyl-tRNA (tRNA ^{Lys}) Synthetase Antibodies	125
M3R Antibodies	125
Mas Antibodies	127
MBL Antibodies	127
MCV Antibodies	128
MDA5 Antibodies	129
Mi-2 Antibodies	131
Midbody Antibodies	133
MJ Antibodies	135
MMP Antibodies	135
MMP1 Antibodies	136
MMP3 Antibodies	136
Mpp1 Antibodies	136
Mpp10 Antibodies	137
MSA Antibodies	138
Myeloperoxidase Antibodies	140
Myosin Antibodies	142
Nedd5 Antibodies	142
Neutrophil Specific Antibodies	143
NMDAR Antibodies	144
NOR-90 Antibodies	146
NR2 Antibodies	148
Nucleolar Antibodies	148
Nucleolin Antibodies	149
Nucleophosmin Antibodies	150
Nucleosome Antibodies	151
NuMA Antibodies	153
NXP2 Antibodies	155
OJ Antibodies	156
oxLDL Antibodies	157
PAD3 Antibodies	158

PAD4 Antibodies	159
pANCA (P-ANCA)	159
PCNA Antibodies	161
PDGF Receptor (PDGFR) Antibodies	163
Pentraxin-3 Antibodies	163
Perinuclear Factors (PNF)	163
Phosphatidic Acid (PA) Antibodies	164
Phosphatidylcholine (PC) Antibodies	165
Phosphatidylethanolamine (PE) Antibodies	165
Phosphatidylinositol (PI) Antibodies	167
Phosphatidylserine (PS) Antibodies	168
Phospholipid (PL) Antibodies	169
PL-7 Antibodies	173
PL-12 Antibodies	174
PLA2R Antibodies	176
PM-1 Antibodies	176
PMS1 Antibodies	176
PM/ScI Antibodies	177
PM/ScI-75 Antibodies	180
PM/ScI-100 Antibodies	180
Poly (ADP-Ribose) Polymerase (PARP) Antibodies	181
Proteasome Antibodies	182
Proteinase 3 Antibodies	183
Protein C Antibodies	185
Protein S Antibodies	186
Prothrombin Antibodies	187
RA33 Antibodies	189
Replication Protein A (RPA) Antibodies	191
Rheumatoid Factors (RF)	192
Ribosomal Antibodies	194
Ribosomal P Protein (RPP) Antibodies	196
Ribosomal RNA Processing (Rrp) Protein Antibodies	198
RNA Antibodies	198
RNA Helicase II Antibodies	199
RNA Helicase A (RHA) Antibodies	199
RNAP-I Antibodies	200
RNAP-II Antibodies	200
RNAP-III Antibodies	201
RNA Polymerase (RNAP) Antibodies	201
Ro52/TRIM21 Antibodies	203
Ro60 Antibodies	205
Ro/SS-A Antibodies	206

28S rRNA Antibodies	210
Rrp Antibodies	210
S10 Antibodies	211
Sa Antibodies	211
SAE Antibodies	212
SAP Antibodies	212
SC Antibodies	212
Scl-70 Antibodies	212
Single-Stranded DNA (ssDNA) Antibodies	215
Sip1 Antibodies	216
Sm Antibodies	217
snoRNP Antibodies	219
snRNP Antibodies	219
SR Protein Antibodies	221
SRP Antibodies	222
SS-56 Antibodies	224
SS-A Antibodies	224
SS-B Antibodies	224
ssDNA Antibodies	224
Threonyl-tRNA (tRNA ^{Thr}) Sythetase Antibodies	225
Thrombomodulin Antibodies	225
Th/To Antibodies	225
TIF-1 Antibodies	227
Topoisomerase I Antibodies	228
Topoisomerase II Antibodies	229
TRIM21 Antibodies	229
Trimethylguanosine Antibodies	229
U1-RNP Antibodies	230
U2-RNP Antibodies	231
U4/U6-RNP Antibodies	231
U5-RNP Antibodies	231
U7-RNP Antibodies	232
U11-RNP Antibodies	232
U11/U12-RNP Antibodies	232

Part 2

Systemic Autoimmune Diseases – Syndromes, Diagnostic Criteria, Symptoms

Abortion, spontaneous	234
Acidosis, renal-tubular	234
Acro-osteolysis	234
Addison's disease	234
Adrenocortical failure	234
Alopecia	234
Alveolitis	235
Amaurosis fugax	235
Amyopathic dermatomyositis	235
ANCA-associated vasculitis	236
Anemia	236
Ankylosing spondylitis (AS)	237
Anti-GBM-Disease	238
Anti-Jo-1 syndrome	238
Antiphospholipid syndrome (APS)	238
Anti-SRP syndrome	241
Antisynthetase syndrome	242
Anti-TNF-induced lupus (ATIL)	242
Arteriitis temporalis	243
Arthralgia	243
Arthritis	244
Autoimmune myositis	244
Behçet disease	244
Bronchial asthma	246
Budd-Chiari syndrome	246
Butterfly rash	246
Calcinosis cutis	246
Cardiomyopathy	246
"Catastrophic" APS	247
Cavernous sinus thrombosis	248
Cerebral infarction	248
Cerebral ischemia	249
Chorea	249
Churg-Strauss syndrome (CSS)	249
Claudication of extremities	249
Claudication of masticatory muscles	249
Cogan's syndrome	249
Congenital heart block	250
Conjunctivitis	250

Connective tissue diseases	250
Creatine kinase.	251
CREST syndrome	251
Cryoglobulinemia.	251
Cryoglobulinemic nephropathy	252
Cryoglobulinemic purpura	252
Cryoglobulinemic vasculitis.	252
Cutaneous leukocytoclastic vasculitis	253
Dementia, multi-infarct.	253
Dermatomyositis (DM)	253
Diffuse alveolar hemorrhage (DAH)	254
Diffuse parenchymal lung disease	256
Discoid lupus erythematosus (DLE)	256
Drug-induced lupus (DIL)	256
Encephalopathy	257
Eosinophilia	257
Eosinophilic granulomatosis with polyangiitis (EGPA)	258
Epilepsy.	258
Episcleritis.	258
Erythema	259
Esophageal dysfunction.	259
Evans syndrome	259
Facial paresis	259
Felty's syndrome	259
Fibrosing alveolitis	260
Fingertip necrosis.	260
Giant cell arteritis	260
Glomerulonephritis	261
Glomerulosclerosis	261
Goodpasture's disease	262
Gottron's sign	262
Granulomatosis with polyangiitis (GPA)	262
Guillain-Barré syndrome	264
Headache	265
Hemianopia	265
Hemophagocytic lymphohistiocytosis (HLH)	265
Hemorrhagic alveolitis.	265
Henoch-Schönlein purpura	266
Hepatic infarction	266
Hepatomegaly	266
Horton's disease.	266
Hypereosinophilia	266
Hyperferritinemia	266

Hypergammaglobulinemia	267
Hypersensitivity vasculitis	267
Hypertension	267
Hypocomplementemic urticarial vasculitis syndrome (HUVS)	268
Idiopathic inflammatory myopathies (IIM)	268
Idiopathic interstitial pneumonia (IIP)	270
Idiopathic myositis	271
Idiopathic pulmonary fibrosis (IPF)	271
IgA nephropathy	272
IgA vasculitis	272
IgG4-related disease	273
Interstitial lung disease (ILD)	274
Intestinal necrosis	275
Intracardiac thrombus	275
Juvenile chronic arthritis (JCA)	275
Juvenile dermatomyositis	278
Juvenile idiopathic arthritis (JIA)	279
Juvenile rheumatoid arthritis (JRA)	279
Juvenile scleromyositis	279
Kawasaki disease	280
Leukocytopenia	281
Leukocytosis	281
Libman-Sacks endocarditis	281
Lilac rings	281
Livedo reticularis/racemosa	281
Lymphadenopathy	282
Lymphocytopenia	282
Macrophage activation syndrome (MAS)	282
Malabsorption	284
Mechanic's hands	284
Membranous nephritis/nephropathy (MN).	284
Meningitis, aseptic.	285
Mesenteric infarction	285
Microscopic polyangiitis (MPA).	285
Microstomia	285
Migraine, atypical	286
Mixed connective tissue disease (MCTD)	286
Moschkowitz's syndrome	289
Mucocutaneous lymph node syndrome	289
Muscle weakness.	289
Muscular atrophy.	289
Myalgia	289
Myocardial infarction	290

Myoglobin	290
Myositis overlap syndromes	290
Necrotizing autoimmune myopathy (NAM)	290
Neonatal lupus erythematosus (NLE).	292
Neonatal lupus syndromes	292
Nephritis	292
Neuropathy	293
Organic brain syndrome	293
Otitis externa	293
Otitis media	293
Overlap syndromes	294
Pancreatic infarction	294
Pancreatitis	294
Panniculitis	294
Parotitis	294
Pericardial effusion	294
Pericarditis	295
Peritonitis	295
Photosensitivity	295
Pleuritis	295
Polyarteritis nodosa	295
Polymyalgia rheumatica (PMR).	296
Polymyositis (PM)/dermatomyositis (DM).	298
Polymyositis/scleroderma overlap	300
Polyneuritis, cranial	300
Posterior reversible encephalopathy syndrome (PRES)	300
Primary Sjögren's syndrome	301
Proteinuria	301
Pseudocaverns	301
Psychosis	301
Ptoxis	302
Pulmonary arterial hypertension (PAH)	302
Pulmonary fibrosis	302
Pulmonary hemorrhage	302
Pulmonary infiltrates	303
Pulselessness	303
Purpura	303
Raynaud's phenomenon	303
Relapsing polychondritis	304
Retinal ischemia	304
Retinitis	305
Rheumatoid arthritis	305
Rheumatoid nodules	307

Rhinitis	307
Rhupus	308
Saddle nose	308
Scleritis/episcleritis	308
Sclerodactyly	308
Scleroderma	308
Scleroderma/myositis overlap	308
Scleroderma renal crisis (SRC)	309
Scleroderma spectrum disorder	309
Secondary Sjögren's syndrome	309
Sensorineural hearing loss	309
Sharp syndrome	310
Sine syndromes	310
Sinusitis	311
Sinus vein thrombosis	311
Sjögren's syndrome (SJS)	312
Sneddon's syndrome	315
Spinal infarction	316
Splenomegaly	316
Spondyloarthritis (SpA)	316
Spondyloarthropathies (SpA)	318
Statin related myopathy	319
Still's disease	319
Stroke	319
Subacute cutaneous lupus erythematosus (SCLE)	319
Systemic autoimmune rheumatic diseases (SARD)	320
Systemic lupus erythematosus (SLE)	320
Systemic sclerosis (SSc)	325
Systemic sclerosis sine scleroderma (ssSSc)	329
Takayasu arteritis	331
Telangiectasia	331
Temporal arteritis	332
Thrombocytopenia	332
Thrombocytosis	332
Thrombosis	332
Thrombotic thrombocytopenic purpura (TTP)	332
Thyroiditis	333
Tolosa-Hunt syndrome	333
Transitory ischemic attacks (TIA)	333
Transverse myelitis	333
Ulcers	333
Undifferentiated connective tissue disease (UCTD)	334
Urticaria	335

Valvular heart disease 335

Vasculitides..... 335

Vertigo 337

Wegener’s granulomatosis (WG) 337

Xerostomia 337

Abbreviations 339

Appendices..... 343

Preface, 3rd edition

Eight years have already passed since the publication of the last edition of this diagnostic reference. Studies and reports of new autoantibodies and their clinical associations remain a very dynamic field of study. As examples, novel classification criteria for rheumatoid arthritis that now include autoantibodies against citrullinated protein/peptide allowing an earlier and more accurate diagnosis have been created and evaluated; novel diagnostic and/or pathogenic autoantibodies in patients with autoimmune inflammatory myopathies, systemic sclerosis and spondyloarthropathies have been described. In addition, novel assays for autoantibody determinations have been developed and transferred into routine diagnostics. Furthermore, novel results of evaluation studies and meta-analyses have led to a reassessment of some of the clinical relevances of some autoantibody specificities. All these aspects required an updated and timely completion of this volume to meet the requirements of a comprehensive and useful reference book for the serological diagnosis of autoimmune diseases as well as clinically relevant autoimmune research. We want to thank all mindful and critical readers for their useful hints since the publication of the last edition.

Karsten Conrad
Marvin J. Fritzler
Falk Hiepe
Werner Schöblier

Preface, 1st edition

Among the challenges facing the new millennium physician are tremendous changes in biomedical and information technologies that are rapidly changing the nature and complexity of clinical practice. Since the discovery of the LE cell over 50 years ago, there has been a logarithmic increase in the description and clinical application of autoantibodies in an ever-widening spectrum of diseases. Systemic rheumatic diseases are among the most complex of these diseases because the clinical presentation and constellation of findings are in part reflected by the spectrum of autoantibodies found in these conditions. The litany of autoantibody acronyms, designations and descriptors include Sm, dsDNA, SS-A/Ro, SS-B/La, U1RNP, Jo-1, topo-I, CENP, Ku, Ki, Sa, and ribo P, to name a few. This 'antibody alphabet soup' has threatened to move clinical diagnostics into a literal Tower of Babel.

It is important to appreciate how the 'antibody alphabet soup' can be useful in the diagnosis and management of systemic rheumatic diseases. The applications are as varied and rich as are the multiplicity of the autoantibody specificities. Certainly, autoantibody testing is not required to make a diagnosis in a woman who presents with a photosensitive skin rash, pericarditis, glomerulonephritis, anemia and psychosis. This patient clearly has SLE and the detection of autoantibodies confirms the obvious. What may not be as clear is that the presence of anti-dsDNA could correlate with nephritis and the presence of anti-ribo P may indicate manifestations of central nervous system lupus in the presence of confounding factors such as infections and drug use. In addition, not all patients present with classical "textbook" features of systemic rheumatic diseases have an identifiable autoantibody. Unfortunately, in many cases the time interval from the onset of symptoms to a confirmed diagnosis and meeting established criteria for the classification of disease, can be measured in decades. Thus, when there is limited (*forme fruste*) disease or a single disease manifestation, the detection of serum autoantibodies can play an important role in raising the suspicion of evolving disease and forecasting prognosis. A good example is the use of autoantibodies in the initial evaluation of Raynaud's phenomenon. If the ANA and other autoantibody tests are negative, the likelihood that his patient has primary Raynaud's disease is likely and the concern that the clinical course will transform into systemic rheumatic disease is lessened.

On the other hand, ample clinical studies have shown that the presence of anti-topo-I (Scl-70) is a harbinger of diffuse scleroderma, antibodies to CENP are more predictive of the limited form of the disease, and the presence of anti-PM/Scl, indicates a scleroderma-polymyositis overlap syndrome. There are many other examples of the clinical utility of autoantibody testing in isolated clinical scenarios such as polyarthritis, myopathies, neuropathies, cytopenias, and vasculopathies that are characteristic, but not specific for, any single systemic rheumatic disease. In many of these instances the presence of one or more 'alphabet soup' antibodies can be a prologue to diseases that are likely to evolve during patient follow-up.

While the diagnosis of *forme fruste* disease is an important use of autoantibody testing, another valuable use is that they provide an understanding of the pathogenesis. This has been clearly illustrated with the subsets of disease such as neonatal lupus syndrome, subacute cutaneous lupus, homozygous C2 deficiency, interstitial lung disease, granulocytopenia, and Sjögren's syndrome that are strongly associated with anti-SS-A/Ro. Compelling evidence shows that anti-SS-A/Ro binds with the cognate antigen in the fetal heart and in keratinocytes exposed to ultraviolet light. On the other hand, it is not clear how or if the same antibody participates in the development of keratoconjunctivitis sicca. The demonstration that ribosomal P proteins and other autoantigens are found on the surface of some normal and apoptotic cells may provide an important clue to their potential pathogenic role. The notion that some autoantibodies may be fingerprints incriminating a cause or etiology of the disease are also being clarified. For example, antibodies to fibrillarin (U3-RNP) are induced in certain strains of mice by heavy metal exposure and systemic sclerosis patients with these autoantibodies have high levels of urinary mercury.

The future of autoantibody testing can be cast into at least four arenas. First, the rapid advancement of new technologies (autoantigen arrays, microfluidics and nanotechnology) will change the complexion of the autoantibody testing by providing a wealth of serological information that will almost certainly challenge current paradigms and clinical associations. It is now possible to use a drop of blood to analyze serum for the presence of over 100 different autoantibodies in a single test that can be completed and reported within minutes. Second, it is anticipated that autoantibody testing will be a critical part of monitoring and evaluating patients placed on a variety of the newer biological therapeutics. For example, it is increasingly clear that interferon and tumor necrosis factor blockade therapies are associated with the induction of autoantibodies and, in some cases, full blown disease. Interestingly, these observations fall on the historical evidence that drugs such as procainamide and hydralazine can induce autoantibodies and lupus syndromes. Third, it is likely that autoantibody testing will replace more invasive and costly diagnostic techniques such as the salivary gland biopsy for Sjögren's syndrome, the small bowel biopsy for coeliac disease, the nerve and skin biopsy for vasculitis, the muscle biopsy for myositis, and many others. Fourth, carefully designed

studies that assess the cost effectiveness of autoantibody testing are required. On one hand, there is the notion that in many patients, including the woman with unequivocal features of SLE described above, that even the relatively inexpensive autoantibody test is superfluous and not cost effective. However, the implications of longer term health care costs of missing an early diagnosis in a patient with *forme fruste* disease must also be carefully considered. A cost-effective and rational approach to autoantibody testing algorithms and clinical practice guidelines are overdue. Clinical studies to address these issues will prove worthwhile and save patients from needless, expensive and invasive tests, and missed diagnosis that can lead to significant morbidity and mortality.

This book and reference guide is intended to assist the physician understand and interpret the variety of autoantibodies that are being used as diagnostic and prognostic tools for patients with systemic rheumatic diseases. Although the landscape of autoantibody testing continues to change, this information will be a useful and valuable reference for many years to come.

Marvin J. Fritzler

Notes for the Use of this Book

This reference book on the serological diagnosis of systemic autoimmune diseases is divided into two main sections. The autoantibodies observed in autoimmune diseases are described in alphabetical order in Part 1, and autoimmune disorders as well as symptoms that indicate the possible presence of an autoimmune disease are listed in Part 2. Guide marks (the symbol “➤”) were inserted to ensure fast and easy cross-reference between symptoms, a given autoimmune disease and associated autoantibodies. Bibliographic references were omitted due to the broad scope of the subject matter. Only the first authors of historical or some important recent publications have been named.

With some exceptions (e. g., antinuclear antibodies) the prefix “anti-” was omitted for better clarity of alphabetization. Anticentromere antibodies, for example, are listed as “centromere antibodies”. In as far as they were known to the authors, synonyms or alternative names for the antibodies were also listed. Obsolete terminology is indicated as such, and the names preferred by the authors are used in the alphabetical index.

The autoantibody description section begins, in some cases, with a brief introduction or historical account. This is followed by information on the target structures (autoantigens), detection methods, clinical relevance, and indications for testing of the autoantibody.

The authors’ rating of the clinical relevance of each autoantibody listed in the book is indicated using variable coloring and lettering.

**White Letters on
Green Background**

These are autoantibodies of high diagnostic relevance (markers for diagnosis, prognosis or monitoring) that can usually be determined in all laboratories.

**Black Letters on
Medium Green Background**

These are diagnostically relevant autoantibodies that are not measurable in all laboratories and therefore are determined in specialized laboratories only.

**Black Letters on
Light Green Background**

The clinical relevance of these antibodies is (still) unclear due to their very low frequency of detection, discrepancies between the findings of different studies (lack of comparability due to differences in study design, methodology, ethnic differences, etc.), methodological problems, or preliminary nature of study findings.

**Black Letters on
White Background**

These autoantibodies are currently not clinically relevant, are no longer clinically relevant, or are clinically relevant only in isolated cases. This can also include disease-specific autoantibodies if their testing does not provide any added diagnostic advantages over other parameters.

Autoantibodies – Definitions and Characteristics

Autoantibodies are a very heterogeneous group of antibodies with respect to their specificity, induction, effects, and clinical significance.

Autoantibodies

Definition and Characteristics

- Autoantibodies are immunoglobulins (= antibodies) directed against endogenous antigens (= autoantigens), such as:
 - Proteins (e. g., intracellular enzymes, receptors, structural proteins)
 - Glycoproteins (e. g., beta-2 glycoprotein I)
 - Nucleic acids (e. g., DNA, RNA)
 - Phospholipids (e. g., cardiolipin)
 - Glycosphingolipids (e. g., gangliosides)
- Autoantibodies are detectable in serum and in certain other body fluids (e. g., synovial fluid, cerebrospinal fluid). Depending on the type of target structure recognized, they may also be bound in tissue (e. g., autoantibodies at autoimmune blistering diseases).
- Autoantibodies may be induced by different mechanisms (= non-natural or pathological autoantibodies) or may occur without such induction as part of the natural repertoire (= natural autoantibodies). Natural autoantibodies play a more or less physiological role (e. g., first line of defense against infections, immunoregulation), whereas non-natural autoantibodies can exert pathogenetic effects (e. g., block or stimulate receptors).
- A number of non-natural autoantibodies induced specifically or predominantly in certain diseases are of great clinical relevance regardless of whether they are pathogenetic or not.

Autoantibodies in the Diagnosis of Autoimmune Diseases

The prevalence of autoimmune diseases in the population (3 - 5 %) underlies the importance of autoantibody diagnostics in the public health sector. Autoimmune thyroid diseases are currently considered to be the most common autoimmune diseases, followed by rheumatoid arthritis, antiphospholipid syndrome and autoimmune liver diseases. Nonetheless, the prevalence of most autoimmune diseases defined so far is low. This reference book deals with systemic autoimmune diseases and the autoantibodies associated with them (non-organ-specific and neutrophil-specific autoantibodies). The autoantibodies relevant for diagnosis of organ-specific autoimmune diseases are covered in another volume. The systemic autoimmune diseases include chronic inflammatory rheumatic diseases (connective tissue diseases, rheumatoid arthritis, systemic vasculitides) and antiphospholipid syndrome. Organ-specific autoimmune diseases which may develop systemic manifestations will not be covered in this volume.

Methodological Considerations when Testing for Autoantibodies

The diagnostically relevant autoantibodies are heterogeneous with respect to their fine specificities, i. e., they recognize a variety of epitopes. As a result, different assays often detect different subpopulations of autoantibodies. The test results for a particular autoantibody specificity can therefore vary from one method to another. This has the following consequences in practice:

1. The possibility of false-positive or false-negative test results can never be reliably ruled out if only one detection method is used to determine the presence of a given autoantibody specificity. Combined screening for antinuclear antibodies by way of indirect immunofluorescence (IIF) followed by differentiation of autoantibody specificity via enzyme immunoassay (EIA) and other novel technologies has proven to be an effective approach to serological diagnosis of connective tissue diseases. Control tests should be performed whenever negative nuclear fluorescence is found in combination with a positive result for a given ANA specificity (e. g., ➤ dsDNA, ➤ Sm, or ➤ U1-RNP antibodies) or whenever

negative cytoplasmic fluorescence is found in combination with a positive result for a given anticytoplasmic antibody specificity (e. g., ➤ Jo-1 antibody). When this constellation (IIF negative, EIA positive) is found, the diagnostic value of the EIA result is limited, even when attempting to exclude false-positive results (see also point 3).

2. There are now a number of different assay platforms available to detect autoantibodies. The time-honored indirect immunofluorescence test continues to be widely used as a screening tool. Assays that allow rapid and specific identification of autoantibodies include enzyme immunoassays (EIA), line immunoassays (LIA), chemiluminescence immunoassays (CIA), addressable laser bead immunoassays (ALBIA) and other microbead based assays.
3. The diagnostic value of an autoantibody specificity varies according to the type of detection method used. Higher assay sensitivity usually results in higher diagnostic sensitivity, but often results in a lower specificity of a given autoantibody for the corresponding disease. For example, autoantibodies to various "extractable nuclear antigens" determined by double radial immunodiffusion (Ouchterlony technique) are highly specific for connective tissue diseases though the sensitivity is limited. The use of highly sensitive enzyme immunoassays increases the diagnostic sensitivity, but usually does so at the expense of diagnostic specificity. The optimal sensitivity/specificity ratio of a new assay should therefore be carefully determined before the assay is introduced for routine diagnostics. Such an analysis should also take individual laboratory differences into account (available range of methods or possibilities for cooperation with reference laboratories, experience of the clinical pathologist and degree of cooperation with referring physicians). The limit values recommended or specified by the manufacturers of commercial assays cannot always be used without reservation. Differential grading of reference ranges has proven to be effective (e. g., borderline or weakly positive, positive, strongly positive). This requires close cooperation between the laboratory and the clinician, which can be difficult due to the common practice of transferring the samples to an "industrialized" laboratory.

If only enzyme immunoassays are available for determination of autoantibodies, the following rule of thumb applies: The higher the titer, the more reliable the test result. However, high-titred false-positive results due to reactivities against proteins used to block free binding sites on the microtiter plate must be excluded (β -casein antibodies or other antibodies against milk proteins found in patients with milk intolerance may produce high-titred EIA results if used as blocking agents). Another important consideration is that titers of some autoantibody specificities (e. g., ➤ ANCA and ➤ dsDNA antibodies) can be correlated with disease activity.

All physicians want the results of laboratory tests to be reproducible and comparable with the results of other tests from other laboratories. But the standardization

of the determination of autoantibodies is still in the infancy. A start, and considerable help in respect of standardization, is the production of so-called standard sera and reference sera. Such standard sera are given by definition a certain concentration of international units (IU/ml). In the case that the sera are not suitable for quantitative determinations, the preparation can be accepted by the IUIS and WHO as a reference preparation. Standard sera and reference sera are available at the Center for Disease Control (CDC), USA, the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), the Netherlands, the National Institute for Biological Standards and Control (NIBSC), UK, and the companies Inova Inc. (USA) and American Diagnostica Inc. (AD), USA. Recommendations for an improved standardization of indirect immunofluorescence as well as enzyme immunoassays are compiled from the Clinical and Laboratory Standards Institute (CLSI) (document I/LA2-A2).

Because the amount of international standards is limited, most of the manufacturers of immunodiagnostic test kits use their own in house standards. These standards should be absolutely calibrated against the international “primary standards”. Only in this case the in house standards should be used as “secondary standards”. This calibration should be done with each lot of manufacturing immunodiagnostic test kits.

The reference preparations are very helpful to check the sensitivity and specificity of test kits for detection of ANA/ENA-antibodies, and therefore, a necessary tool for manufacturing immunodiagnostic test kits for autoantibody detection and should be used with each lot of manufactory immunodiagnostic test kits.

Clinical Relevance of Autoantibodies

Testing for autoantibodies can be helpful or necessary for the diagnosis, differential diagnosis, prognostication, or monitoring of autoimmune diseases. The diagnostic sensitivity and specificity, the positive and negative predictive values as well as the likelihood ratios of a given autoantibody for the corresponding disease are important criteria for evaluating its diagnostic relevance for a particular disease. The higher these parameters, the more valuable the antibody is for the corresponding diagnosis. As was already mentioned in the discussion of methodological aspects, these parameters differ when using different tests for detection of a particular autoantibody. The diagnostic sensitivity is the proportion of patients with the disease who are correctly identified by the autoantibody test (quotient of true positive tests and total number of patients with the disease). The diagnostic specificity is the proportion of patients without the disease who are correctly identified by the autoantibody test (quotient of true negative tests and total number of patients/healthy volunteers without the disease). Diagnostic sensitivity and specificity figures provided under the heading “clinical relevance” for many autoantibodies should be regarded as guiding numbers only. These values vary

Table 1. International standards and reference sera.

Autoantibody or IIF staining pattern	Name	Supplier
➤ ACPA	CDC 17	CDC
➤ Antinuclear antibodies (ANA)	WHO 66/233	CLB
➤ ANA homogenous/dsDNA	CDC 1	CDC
➤ ANA speckled	CDC 3	CDC
➤ β 2 glycoprotein I (IgG)	HCAL/CDC 13	CDC/INOVA*
➤ β 2 glycoprotein I (IgM)	EY2C9/CDC 14	CDC/INOVA
➤ Cardiolipin (IgA)	aCL IgA ("Harris-Standard")	AD
➤ Cardiolipin (IgG)	aCL IgG ("Harris-Standard")	AD
➤ Cardiolipin (IgG)	HCAL/CDC 13	CDC/INOVA
➤ Cardiolipin (IgM)	aCL IgM ("Harris-Standard")	AD
➤ Cardiolipin (IgM)	EY2C9 /CDC 14	CDC/INOVA
➤ Centromere	CDC 8	CDC
➤ dsDNA	WHO-Wo/80	CLB
➤ Jo-1/histidyl-tRNA synthase	CDC 10	CDC
➤ La/SS-B (ANA speckled)	CDC 2	CDC
➤ Myeloperoxidase	CDC 15	CDC
➤ Nucleolar	CDC 6	CDC
➤ PM/Scl	CDC 11	CDC
➤ Proteinase 3	CDC 16	CDC
➤ Rheumatoid Factor (RF)	WHO-64/1	CLB
➤ Ribosomal-P	CDC 12	CDC
➤ Ro60/SS-A	CDC 7	CDC
➤ Topoisomerase I/Scl-70	CDC 9	CDC
➤ Sm (U2-U6 RNP)	CDC 5	CDC
➤ U1-RNP	CDC 4	CDC
➤ U1-RNP	WHO-anRNP	CLB

Abbreviations: AD, American Diagnostica Inc., USA; CDC, Center for Disease Control, USA; CLB, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, The Netherlands; PM/Scl, polymyositis-scleroderma exosomal antigen; Sm, Smith autoantibody; WHO, World Health Organization.

* INOVA: INOVA Diagnostics, San Diego, CA, USA

according to the diagnostic kit or platform (see above) and study design used. In addition, ethnic, geographic and genetic differences in the expression of certain autoimmune responses, which can be quite significant, must also be considered.

Ideally, the diagnostic sensitivity and specificity must both be 100%; however, none of the diagnostically relevant autoantibodies achieve this goal. Some autoantibodies (e. g., ➤ PL-7 antibodies used to diagnose polymyositis) achieve almost 100% specificity but have a very low sensitivity. Others (e. g., ➤ Ro/SS-A antibodies used to diagnose Sjögren's syndrome) have a low specificity but high sensitivity. Autoantibodies involved in the pathogenesis of a given disease (e. g., ➤ proteinase-3 antibodies used to diagnose granulomatosis with polyangiitis (Wegener's granulomatosis)) generally achieve very high values for both of the two diagnostic parameters. Since the titers of these autoantibodies are usually associated with disease activity, their high sensitivity applies "only" during the active phases of disease.

Some autoantibodies have been identified as criteria for classification of certain diseases, e. g., the criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) for classification of ➤ systemic lupus erythematosus (SLE) or the ➤ rheumatoid arthritis. Autoantibodies that are not highly specific for the respective disease (e. g., ➤ rheumatoid factors for rheumatoid arthritis; ➤ phospholipid antibodies for ➤ antiphospholipid syndrome) may also be defined as classification criteria, but are considered to be of diagnostic importance only when they occur in conjunction with typical symptoms of the disease. Fortunately, novel classification criteria have been quite recently developed that include disease specific autoantibodies (e. g., ➤ centromere, ➤ topoisomerase I and ➤ RNA polymerase III antibodies used to diagnose ➤ systemic sclerosis). In addition to "establishing the diagnosis" in patients with typical symptoms, a number of disease-specific autoantibodies are very important for early diagnosis if there is a monosymptomatic, oligosymptomatic (forme fruste), or atypical presentation of the disease (e. g., ➤ aminoacyl-tRNA synthetase antibodies to diagnose systemic autoimmune disorder in case of ➤ idiopathic interstitial lung disease).

Which course of action should be taken when disease-specific autoantibodies are detected in a patient/volunteer without any typical symptoms? The first step is to make sure that the test was not a false-positive (see "Methodological Considerations when Testing for Autoantibodies"). The reporting reference laboratory should be consulted if necessary. If the results are classified as actual positive binding of the autoantibody to the corresponding autoantigen (= correct positive test), the test should be repeated within 3 to 6 months (the ➤ phospholipid antibody test should be repeated after 12 weeks). If the antibodies have disappeared, the positive result may have been due to polyclonal B cell stimulation in the course of an infection; this may result in positive reactivity to certain autoantibodies (usually low titers) when highly sensitive tests are used. One must also be aware that disease-specific autoantibodies can also occur in conjunction with tumors. When

persistence or even a rise of the autoantibody titer is observed, the clinical and serological course of the disease should be monitored in one or two-year intervals (depending on the expected course of the disease).

Part 1

Autoantibodies in Systemic Autoimmune Diseases

ACPA

Anti-citrullinated protein/peptide antibodies (ACPA) is the collective name for all autoantibodies directed against citrullinated proteins or peptides. See ➤ citrullinated protein/peptide antibodies.

NOTE: ACPA is also a former term of antineutrophil cytoplasmic antibodies (ANCA) and a term for anticytoplasmic antibodies detected by indirect immunofluorescence on HEp-2 cells.

Alanyl-tRNA (tRNA^{Ala}) Synthetase Antibodies

See ➤ aminoacyl-tRNA synthetase antibodies, ➤ PL-12 antibodies.

Alpha-Actinin Antibodies

Cross-reactive ➤ dsDNA antibodies that are associated with lupus nephritis (Re-naudineau et al., 2007). The controversial nephritogenic potential of alpha-actinin antibodies is discussed (Kalaaji et al., 2006; Zhao et al., 2006; Manson et al., 2009). The modulation of alpha-actinin expression in/on mesangial cells of the kidney may contribute to the susceptibility for lupus nephritis.

Alpha-Enolase Antibodies**Autoantigen**

The ubiquitous glycolytic enzyme α -enolase is 82% homologous with the other two isoforms, β - and γ -enolase, and homologous with tau, a soluble lens protein of the crystalline family.

Detection Methods

Enzyme immunoassay (EIA) or Western blot (WB) using purified α -enolase.

Clinical Relevance

The induction of autoantibodies in various diseases against the ubiquitously occurring α -enolase may be a result of microbial infections or hyperproliferative processes in tissues under certain pathophysiological conditions. A pathogenic effect on endothelial cells via complement activation, inhibition of the binding of plasminogen to α -enolase and induction of apoptosis is discussed.

The occurrence of α -enolase antibodies in systemic autoimmune diseases is summarized (for review see Terrier et al., 2007; α -enolase antibodies in organ specific autoimmune disease: see K.Conrad, W. Schöblier, F. Hiepe, M. J. Fritzler: "Autoantibodies in Organ Specific Autoimmune Diseases – A Diagnostic Reference", Pabst Science Publishers, Lengerich 2011):

- Parameter of nephropathy: Detected in 69 % of patients with primary membranous nephropathy and in 58 % of those with the secondary forms, e. g., patients with ➤ systemic lupus erythematosus (SLE) and ➤ rheumatoid arthritis (RA). Detected in 27 % of SLE patients and associated with active renal disease. Alpha-enolase is a target of nephritogenic ➤ dsDNA and non-DNA antibodies (Migliorini et al., 2002). In mixed ➤ cryoglobulinemia, α -enolase antibodies were found in 3 % of patients with nephritis but not in patients without nephritis.
- In patients with ➤ **systemic sclerosis**, α -enolase antibodies were found in up to 30 %. They were associated with diffuse cutaneous scleroderma, pulmonary and vascular involvement (Pratesi et al., 2000).
- Alpha-enolase is a cytoplasmic enzyme of neutrophils and also a minor target of autoantibodies in ➤ **ANCA-associated vasculitides**.
- Alpha-enolase of human dermal microvascular endothelial cells was described as a target of autoantibodies in 37.5% of patients with ➤ **Behçet's disease** (Lee et al., 2003).
- In patients with ➤ **relapsing polychondritis**, α -enolase antibodies were found in 46 % (Tanaka et al., 2006).
- Autoantibodies to alpha-enolase were present in the sera of patients with very early ➤ **rheumatoid arthritis (RA)** and may have prognostic value (Saulot et al., 2002). The binding of those autoantibodies was associated with post-translational modification, e. g., citrullination (Kinloch et al., 2005). Autoantibodies against citrullinated α -enolase were found in 24 – 62 % of RA patients (Lundberg et al., 2008; Fisher et al., 2011). See also ➤ citrullinated protein/peptide antibodies and ➤ CEP-1-antibodies.

Indications

None currently established. It remains to be determined whether testing for these autoantibodies will provide any clinical advantages for diagnosis or prognosis of mixed cryoglobulinemia (renal involvement), retinopathies (paraneoplastic), RA, Hashimoto's encephalopathy or other diseases.

Comments: Alpha-enolase antibodies are a heterogeneous group of autoantibodies that recognize various epitopes of α -enolase proteins (and some of β - and γ -enolase proteins) and perhaps some related proteins as well (e.g., the lens protein tau). Their relationship to ➤ ANCA and ➤ centrosome antibodies (centrosome antibody positive sera detected purified α - and γ -enolase [Rattner et al., 1991; Fritzler et al., 2003]) still needs to be clarified. Further investigations are therefore necessary for differentiation (epitope specificity) and, thus, for improved clinical utility of α -enolase antibodies.

Alpha-Fodrin Antibodies

Autoantigen

The 120 kDa apoptotic cleavage product of alpha-fodrin. Alpha-fodrin is a 240 kDa protein which binds to beta-fodrin or beta-spectrins to form a heterodimer as a part of the eukaryotic cell membrane cytoskeleton. Alpha-fodrin is associated with membrane ion channels and pumps, and appears to be involved in control of secretion from glands.

Detection Methods

WB or EIA using the recombinant antigen or the N-terminal alpha-fodrin peptide RQKLEDSYRFQFFORDAEEL (Shiari et al., 2006; Chen et al., 2007).

Clinical Relevance

- In some studies, alpha-fodrin antibodies were found in patients with primary or secondary ➤ **Sjögren's syndrome** (SjS) and had high sensitivity (> 60 – 93 % depending on classification criteria used) and specificity (93 %) (Witte et al., 2000 and 2003). Other studies, however, showed a lower diagnostic relevance in SjS (Zandbelt et al., 2003; Ruffatti et al., 2004; Sordet et al., 2005; Loch et al., 2008). Different study designs and methodical aspects were suggested for this discrepancy. For example, the antibody titer decreases during immuno-

suppression therapy, explaining lower frequencies in some studies. Furthermore, IgG antibodies in patients with primary SjS are associated with characteristic clinical and immunological features indicative of local (e. g., lymphocytic infiltration of salivary glands) and systemic (e. g., increase of CD71 positive T-helper cells and HLA-DR expressing monocytes) inflammation and thus may serve as markers of disease activity (Willeke et al., 2007). In addition, an increased prevalence of alpha-fodrin antibodies of the IgG isotype in primary SjS patients with shorter disease duration was found suggesting that these antibodies may participate in early pathogenic processes.

- The stringency of criteria used for classification of SjS and disease activity may likely explain the differences in the frequency of alpha-fodrin antibodies between different studies. Using the revised European criteria, the American/European consensus criteria (Vitali et al., 2002) and the highly stringent San Diego criteria (Fox et al., 1986), IgA and/or IgG antibodies against alpha-fodrin were found in 93 % (Witte et al., 2010). IgA antibodies against alpha-fodrin were more prevalent than IgG antibodies (88 % vs 64 %). However, a meta-analysis including 23 studies showed a pooled sensitivity of alpha-fodrin IgG and IgA antibodies of only 28 % and 42 %, respectively (Hu et al., 2013).
- Alpha-fodrin antibodies can be detected in up to 100 % in patients with juvenile onset of SjS, in some cases before ➤ Ro/SS-A or La/SS-B antibody became positive (Kobayashi et al., 2001).
- Alpha-fodrin antibodies were found in high frequency (72 %) in patients with moyamoya disease (Ogawa et al., 2003).
- They are also detectable at higher frequencies in patients with ➤ rheumatoid arthritis (30 – 40 %), ➤ systemic lupus erythematosus (20 %), Graves' ophthalmopathy (31 %), multiple sclerosis (20 %), normal-pressure glaucoma, chronic HCV infection (25%) and Hashimoto thyroiditis (22 %) (Ulbricht et al., 2003; He et al., 2005; Kahali et al., 2005; Grus et al., 2006 ; Szanto et al., 2008; Potthoff et al., 2009). In conclusion, regarding the specificity for SjS, both IgA and IgG antibodies against alpha-fodrin are present in up to 40 % of patients with active inflammatory diseases, but in only 2 % in blood donors. Therefore, antibodies against alpha-fodrin appear to be helpful in the distinction of SjS from fibromyalgia, the main differential diagnosis in clinical practice, but not from SLE or RA (Witte et al., 2007).

Indications

Suspicion of SjS, if Ro/SS-A and/or La/SS-B antibodies are not detectable. The relevance in early diagnosis and monitoring of SjS should be further evaluated. Interestingly, autoantibodies against alpha-fodrin may indicate early active disease, which is still treatable by immunosuppression. It was shown that hydroxychloroquine treatment of SjS patients significantly improves saliva production only in SjS patients with (but not without) antibodies against alpha-fodrin

(Rihl et al., 2009). Therefore, the presence of these autoantibodies may indicate a therapeutic „window of opportunity“ in patients with early (or very early) SjS (Witte et al., 2010).

NOTE: Alpha-fodrin antibodies are not part of the new ACR criteria of the SjS (Shiboski et al., 2012).

Aminoacyl-tRNA Synthetase (ARS) Antibodies

Synonym: Anti-synthetase antibodies.

Collective term for all autoantibodies directed against aminoacyl-tRNA synthetases (ARS). The following ones have been described so far:

- Histidyl-tRNA synthetase antibodies (➤ Jo-1 antibodies),
- Threonyl-tRNA synthetase antibodies (➤ PL-7 antibodies),
- Alanyl-tRNA synthetase antibodies (➤ PL-12 antibodies),
- Isoleucyl-tRNA synthetase antibodies (➤ OJ antibodies),
- Glycyl-tRNA synthetase antibodies (➤ EJ antibodies),
- Lysyl-tRNA synthetase antibodies (➤ SC antibodies),
- Asparaginyl-tRNA synthetase antibodies (➤ KS antibodies),
- Leucyl-tRNA synthetase antibodies,
- Glutaminy-tRNA synthetase antibodies,
- Phenylalanyl-tRNA synthetase antibodies (Zo antibodies),
- Tyrosyl-tRNA synthetase antibodies (Ha antibodies).

Autoantigens

Aminoacyl-tRNA synthetases. These cytoplasmic enzymes catalyze the binding of a specific amino acid to the corresponding transfer RNA (tRNA) molecule. For instance, the amino acid histidine is bound to tRNA^{His} with the aid of histidyl-tRNA synthetase, leading to the formation of histidyl-tRNA complexes.

Detection Methods

- IIF using HEP-2 cells: some sera with this reactivity produce diffuse or fine granular staining of the cytoplasm.

NOTE: The staining pattern is not seen with all sera and when it is seen, it is suggestive of, but not specific for, ARS antibodies.

- Immunodiffusion (Ouchterlony technique) or counter-current immuno-electrophoresis (CIE) using soluble antigens from rabbit thymus or human spleen.

NOTE: This technique has a low sensitivity and does not detect all ARS antibodies.

- WB using HeLa or MOLT4 cell extracts or special aminoacyl-tRNA synthetase preparations.
NOTE: False-negative results are possible.
- EIA, LIA/DIA, CIA or ALBIA using biochemically purified or recombinant aminoacyl-tRNA synthetases.
- Immunoprecipitation (IP), e. g., radioimmunoprecipitation of tRNA from ³²P-labeled cell extracts (HeLa S3 cell lineage).

Comments: Immunodiffusion or CIE, EIA, LIA/DIA, CIA and ALBIA are currently used in routine laboratory testing for determination of ➤ Jo-1, ➤ PL-7, and ➤ PL-12 antibodies. Special myositis-LIAs also allow the determination of EJ and OJ antibodies. However, there is still a strong need for cost-effective and standardized assays for the detection of ARS autoantibodies.

Clinical Relevance

- Anti-ARS autoantibodies are specific markers for the so-called ➤ antisynthetase syndrome (ASS), a subset of the spectrum of the ➤ idiopathic inflammatory myopathies (IIMs). ASS is characterized by multiple organ involvement, primarily ➤ interstitial lung disease (ILD), and is often accompanied by myositis, non-erosive arthritis, Raynaud's phenomenon, "mechanic's hands", skin rashes, sicca syndrome and constitutional symptoms, such as fever. Because ASS lacks diagnostic criteria and can present in different combinations of clinical features, the presence of at least one ARS antibody is required for definite diagnosis. However, diagnosis and management of ASS are still challenging due to often masked and/or non-specific symptoms at the disease onset (Ghirardello et al., 2009).
- Jo-1 antibodies are detectable in 20 – 30 % of patients with IIMs (Selva-O'Callaghan et al., 2006). They were found in 60 – 80 % of ASS patients (Sordet et al., 2006), but also in 10 - 40 % of PM and 2 – 10 % of DM patients (Sordet et al., 2006). PM/DM patients positive for Jo-1 antibodies may have or may develop features of ASS. ARS antibodies other than Jo-1 antibodies are present in less than 5 % of ASS patients (Ghirardello et al., 2011). At least one of the aforementioned ASS antibodies is found in up to 80 % of all patients with myositis and ILD. The ARS antibodies generally do not cross-react or co-exist with others.
- Each ARS antibody seems to be associated with heterogeneous disease expression and severity (Aggarwal et al., 2014), in which lung and joint involvement could be prominent at early disease stages. Patients with ARS antibodies other than Jo-1 antibodies have decreased survival compared to Jo-1 antibody positive patients, probably partly attributable to a delay in diagnosis (Aggarwal et al., 2013).
- The lung manifestation in ARS positive patients may precede myositis (in this clinical subtype ARS antibodies are the most frequently detectable antibodies)

or even may proceed without the development of myopathy (**seropositive amyopathic interstitial lung disease**) (Yoshifuji et al., 2006). ARS autoantibodies have been reported in about 7 % of patients with ➤ idiopathic interstitial pneumonia. Whether such autoantibodies could also have a predictive value for immune mediated ILD has to be further elucidated (Takato et al., 2013).

- Few cases of pulmonary involvement with acute onset and a rapid progression toward respiratory insufficiency (acute respiratory distress syndrome) have been described in ARS antibody positive patients without myositis. It is conceivable that due to the variable clinical forms of IIM, and to the difficulties related to diagnosis, the prevalence of this association is higher than the few reported cases suggest (Bajocchi et al., 2012).
- ARS antibodies other than Jo-1 antibodies can also be associated with necrotizing myopathy or pericarditis (Labirua-Iturburu et al., 2012; Mehndiratta et al., 2012).

Indications

1. Diagnosis/differential diagnosis of myositis.
2. Clinical features indicative for ASS.
3. Interstitial lung disease or acute respiratory failure of unknown origin.

Comments: Even when the conventional tests for Jo-1, PL-7 and PL-12 antibodies are not positive, the detection of immunofluorescence patterns typical of aminoacyl-tRNA synthetase antibodies may still be a valuable diagnostic indicator in patients with suspected idiopathic myositis, especially in those with concomitant ILD. In these cases, the occurrence of other aminoacyl-tRNA synthetase antibodies or KJ antibodies is possible.

Annexin V Antibodies

Autoantigen

Annexin V is a potent Ca^{2+} -dependent anticoagulant protein that is abundant in cells exposed to blood, e. g., platelets, trophoblast (mainly syncytiotrophoblast) and endothelial cells and which activity is based on the high affinity binding to anionic phospholipids and as a result on the inhibition of the phospholipid-dependent coagulation cascade. Annexin V is forming two-dimensional crystals over anionic